References
- World Health Organization. Global report on diabetes [Internet]. Geneva, Switzerland: WHO; 2016. Available at: http://www.who.int/about/licensing/\n http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf [Last accessed 1 September 2017]
- IDF. IDF diabetes atlas, 8th edition [Internet]. Brussels: International Diabetes Federation; 2017. Available at: http://www.diabetesatlas.org/ [Last accessed November 17, 2017]
- Jaacks LM, Siegel KR, Gujral UP, et al. Type 2 diabetes: a 21st century epidemic. Best Pract Res Clin Endocrinol Metab 2016;30:331–43
- Tamayo T, Brinks R, Hoyer A, et al. The prevalence and incidence of diabetes in Germany. Dtsch Arztebl Int 2016;113:177–82
- Jacobs E, Hoyer A, Brinks R, et al. Healthcare costs of Type 2 diabetes in Germany. Diabet Med 2017;34:855–61
- Landgraf R, Kellerer M, Fach E, et al. Praxisempfehlungen DDG/DGIM. Diabetol Stoffwechsel 2016;11:S117–S129
- Gemeinsamer Bundesausschuss. des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII - Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V – Dulaglutid [Internet]. Berlin: Gemeinsamer Bundesausschus; 2015. Available at: https://www.g-ba.de/downloads/39-261-2290/2015-07-16_AM-RL-XII_Dulaglutid_2015-02-01-D-154_BAnz.pdf [Last accessed November 17, 2017]
- American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care. 2017;40:S64–S74
- VersorgungsLeitlinie N. Therapiedes Tyap 2 Diabetes [Internet]. Berlin: NATIONALE VERSORGUNGSLEITLINIEN; 2014. Available at: http://www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/NVL_Typ-2_Therapie-lang_Apr_2014.pdf [Last accessed: 22 March 2018]
- EMA. Summary of product characteristics: Byetta, exenatide BID [Internet]. London: EMA; 2018. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000698/WC500051845.pdf [Last accessed March 29, 2018]
- EMA. Summary of product characteristics: Victoza, liraglutide [Internet]. London: EMA; 2018. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf [Last accessed March 29, 2018]
- EMA. Summary of product characteristics: Bydureon, exenatide QW [Internet]. London: EMA; 2018. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002020/WC500108241.pdf [Last accessed March 29, 2018]
- EMA. Summary of product characteristics: Eperzan, albiglutide [Internet]. London: EMA; 2017. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002735/WC500165117.pdf [Last accessed March 29, 2018]
- EMA. Summary of product characteristics: Trulicity, dulaglutide [Internet]. London: EMA; 2018. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/0028 25/WC500179470.pdf [Last accessed February 19, 2018]
- Lovshin JA. Glucagon-like peptide-1 receptor agonists: a class update for treating type 2 diabetes. Can J Diabetes 2017;41:524–35
- Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728–42
- Alatorre C, Fernández Landó L, Yu M, et al. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide. Diabetes Obes Metab 2017;19:953–61
- Divino V, DeKoven M, Khan FA, et al. GLP-1 RA treatment patterns among type 2 diabetes patients in five European countries. Diabetes Ther 2017;8:1–14
- Divino V, DeKoven M, Hallinan S, et al. Glucagon-like peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries. Diabetes Ther 2014;5:499–520
- McDonell A, Kiiskinen U, Zammit D, et al. Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies. Clin Outcomes Res 2015;7:95
- Fuchs S, Kostev K, Seitz L, et al. Ermittlung der tatsächlichen Tagesdosierung von Liraglutid (PDD) unter realen Versorgungsbedingungen im Hinblick auf die Berechnung von Tagestherapiekosten. Diabetol Stoffwechsel 2011;6:P234
- Lin J, Lingohr-Smith M, Fan T. Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US. Clinicoecon Outcomes Res 2017;9:19–29
- Miller L-A, Burudpakdee C, Zagar A, et al. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany. J Med Econ 2012;15:746–57
- Rhee MK, Slocum W, Ziemer DC, et al. Patient adherence improves glycemic control. Diabetes Educ 2005;31:240–50
- Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712–25
- Stuart BC, Simoni-Wastila L, Zhao L, et al. Increased persistency in medication use by U.S. Medicare beneficiaries with diabetes is associated with lower hospitalization rates and cost savings. Diabetes Care 2009;32:647–9
- Nagrebetsky A, Griffin S, Kinmonth AL, et al. Predictors of suboptimal glycaemic control in type 2 diabetes patients: the role of medication adherence and body mass index in the relationship between glycaemia and age. Diabetes Res Clin Pract 2012;96:119–28
- Richter H, Dombrowski S, Hamer H, et al. Use of a German longitudinal prescription database (LRx) in pharmacoepidemiology. Ger Med Sci 2015;13:Doc14
- Bell KF, Cappell K, Liang M, et al. Comparing Medication Adherence and Persistence Among Patients with Type 2 Diabetes Using Sodium-Glucose Cotransporter 2 Inhibitors or Sulfonylureas. Am Heal drug benefits 2017;10:165–174
- Buysschaert M, D’Hooge D, Preumont V. ROOTS: a multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients. Diabetes Metab Syndr Clin Res Rev 2015;9:139–42
- Gautier J-F, Martinez L, Penfornis A, et al. Effectiveness and persistence with liraglutide among patients with type 2 diabetes in routine clinical practice—EVIDENCE: a prospective, 2-year follow-up, observational, post-marketing study. Adv Ther 2015;32:838–53
- Guo X-H The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide. Curr Med Res Opin 2016;32:61–76
- Otto T, Stralka R, Schimmelpfennig H, et al. Treatment options for patients with progressing type 2 diabetes: What are patients' preferences in Germany when switching from oral to injectable antidiabetic treatment? Gesundh ökon Qual Manag 2016;21:181–198
- Gelhorn H, Poon J-L, Davies E, et al. Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK. Patient Prefer Adherence 2015;9:1611